Impact of KRAS codon-specific mutations on survival of patients with metastatic CRC (mCRC) treated with trifluridine-tipiracil (TAS) plus bevacizumab (Bev): A real-world analysis.
- Giulia Maddalena
- , Ymke van der Pol
- , Zachary Rivers
- , Arvind Dasari
- , Jane E. Rogers
- , Justin Guinney
- , Scott Kopetz
- , Kanwal Pratap Singh Raghav
Research output: Contribution to journal › Review article › peer-review
1
Link opens in a new tab
Scopus
citations